275 Grove St., Suite 101C, Newton, MA 02466
+1 617 454 9300
2520 Meridian Parkway, Research Triangle Park, Suite 200, Durham, NC 27713
+1 919 544 3170
© 2000-2022. Parexel International Corporation.
275 Grove St., Suite 101C, Newton, MA 02466
+1 617 454 9300
2520 Meridian Parkway, Research Triangle Park, Suite 200, Durham, NC 27713
+1 919 544 3170
© 2000-2022. Parexel International Corporation.
Our Clinical Trial Regulatory Services team can help facilitate a seamless experience no matter where in the world you operate. By combining centralized data management with the ability to simultaneously manage multiple regulatory submissions, we can guide you through quicker trial start-up and follow-through.
We are also proud to ease your journey with labelling services in a single location. So whether you need a single label or a full library, we can work it into your full-service clinical trial management solution.
Across your clinical development journey, consider our Clinical Trial Regulatory Services a hub for all. Whether you, a third party, or Parexel are managing your clinical trial, our processes and solutions are designed to bring everyone together. From your submission plan, assembly, and application management through delivery to master archiving, you’ll rest easy knowing all your assets are being managed by a single watchful team.
Preparedness for the Clinical Trials Regulation (EU) 536/2014 will require a wide-ranging cross enterprise business strategy including for both ongoing and new clinical trials to be set up correctly. Are you ready for the change? Download our factsheet to learn more about how Parexel can help you prepare for the transition.
8 things you need to know about eCTDs in China
View now
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
Read now
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
Read now
Communicating Value to Providers and Payers
View now
New endpoints for early-stage cancer are gaining regulatory traction
View now
Making Expedited Regulatory Pathways Work for Global Drug Development Programs
View now
Five lessons for building an external control arm that regulators can use
View now
Three ways to work with the FDA for better patient-focused trials
View now
Browse the Parexel Resource Center for our latest content on clinical trial supplies, logistics, innovation, drug safety, cell & gene therapy, and more!
8 things you need to know about eCTDs in China
View Now
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
Read Now
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
Read Now
Communicating Value to Providers and Payers
View Now
New endpoints for early-stage cancer are gaining regulatory traction
View Now
Making Expedited Regulatory Pathways Work for Global Drug Development Programs
View Now
Five lessons for building an external control arm that regulators can use
View Now
Three ways to work with the FDA for better patient-focused trials
View Now
Expedited Pathways Comparisons - US EU CHN
View Now
Five competencies for operational excellence in cell and gene therapy clinical trials
View Now
Three strategies for articulating a coherent product value story
View Now
How emerging biotechs can enter the Chinese market and prosper
View Now
Maximize the efficiency of regulatory operations with five key competencies
View Now
What to know about FDA INTERACT meetings
View Now
How biotechs can strengthen their value story with advanced analytics
View Now
Crafting a genomics strategy early is key for successful oncology drug development
View Now
Early planning can help you make the most of expedited regulatory pathways
View Now
Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs
Read Now
Biosimilar Development: Are therapeutic clinical trials needed?
Read Now
Four reasons to conduct robust natural history studies before clinical trials
Read Now
The Evolving Cell and Gene Therapy (CGT) Sector in China
Read Now
Virtual meetings are easy, right?
Read Now
Using risk assessment decision tree models to maintain safety and data validity in clinical trials during COVID-19
Read Now
Understanding the COVID-19 regulatory procedures the FDA is using
Read Now
Top 10 Myths About Working with the FDA for an Oncology Drug Approval
Read Now
Three ways to improve your chances that insurers will pay for a new CGT
Read Now
The Great Lockdown of 2020: Will the Life Sciences Emerge Unscathed?
Read Now
The Changing Fortunes of Telemedicine in Europe – Past, Present, and Future beyond COVID-19
Read Now
Restricted pharmaceutical exports from India: Are you ready to mitigate risk of drug shortages?
Read Now
Rescuing Product Approvals from Data Integrity Issues
Read Now
Reimagining the Global Value Dossier - Part 4
Read Now
Reimagining The Global Value Dossier - Part 6
Read Now
Reflections on Cancer Drug Development Strategies with Newly-Introduced Chinese Regulations
Read Now
Rare Disease and Orphan Drug Designations - What You Need to Know
Read Now
Rapid Responders: How Innovative Technologies are Accelerating Development of New Vaccines
Read Now
Putting the Pandemic in Plain Language
Read Now
Perspective on Enforcement Policy for Face Masks and Respirators During the Coronavirus Disease (COVID-19) Public Health Emergency
Read Now
Part Two: The Unique Impact of COVID-19 and Implications for the MSK Industry
Read Now
Parexel on the Pulse
Watch Now
NMPA Guidance on the Management of Clinical Trials during the COVID-19 from July 2020
Read Now
Navigating new steps in how FDA is managing COVID-19 Products
Read Now
Parexel on the pulse
Watch Now
Press announcement: Parexel unveils combined Regulatory & Access consulting organization
Read Now
It’s Not Just Manufacturing – Drug Development Presents Corporate Compliance Risks Too
Read Now
How to align your market access activities with your product value strategy
Read Now
How the UK's HTA Agency Uses Real-World Evidence to Develop Guidance
Read Now
How market exclusivities can affect your development program
Read Now
How COVID-19 is Accelerating Telemedicine Adoption in Asia Pacific
Read Now
GxP On-Site Inspections are Restarting: Preparing for inspections under the “new normal”
Read Now
FDA Inspections and Cleaning
Read Now
Episode 4: Accelerated Regulatory Pathways and Patient Access
Read Now
The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19
Read Now
The impact of COVID-19 on clinical trials in rare disease and oncology
Read Now
Don’t Shortchange Your Due Diligence When It Involves Applications – FDA Won’t
Read Now
Does FDA Consistently Assess Product Quality Risk and Control in Applications?
Read Now
FDA Expectations for Responding to Employees in Pharmaceutical Manufacturing Infected with COVID-19
Read Now
Critical Differences Between a Form FDA 483 and Warning Letters
Read Now
COVID-19 Vaccine Development - Part 3: Late stage clinical development and field trials
Read Now
COVID-19 Vaccine Development - Part 2: Non-clinical and Early phase clinical development
Read Now
CAR-T: How far have we come and where are we going?
Read Now
Capturing the patient voice in market access communications
Read Now
Can FDA Really Do That? Understanding FDA’s Jurisdiction
Read Now
We are always available for a conversation.